Substitute for form 1449/PTO (Revised 07/2007) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/578,400	
			CLIDE	Filing Date	January 3, 2007	
				First Named Inventor	Long	
				Art Unit	1644	
				Examiner Name	Gambel, Phillip	
Sheet	1	of	2	Attorney Docket Number	035784/311256	

	U. S. PATENT DOCUMENTS						
Examiner Initials*			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figure Appear		
	16	US-5,397,703	03-14-1995	de Boer et al.			
	17	US-5,677,165	10-14-1997	de Boer et al.			
	18	US-6,004,552	12-21-1999	de Boer et al.			
	19	US-6,056,959	05-02-2000	de Boer et al.			
	20	US-6,315,998 B1	11-13-2001	de Boer et al.			
	21	US-6,899,879 B2	05-31-2005	de Boer et al.			
	22	US-20070098718 A1	05-03-2007	Long et al.			
	23	US-20070110754 A1	05-17-2007	Long et al.			
	24	US-20070218060 A1	09-20-2007	Long et al.			

		FOREI	GN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	25	WO 94/01547 A3	01-20-1994	Cetus Oncology Corporation		
	26	WO 97/31025 A1	08-28-1997	Chiron Corporation		
	27	WO 99/42075 A2	08-26-1999	Bristol-Myers Squibb Company		
	28	WO 02/028481 A2	04-11-2002	Chiron Corporation		
	29	WO 2005/044294 A2	05-19-2005	Chiron Corporation		
	30	WO 2005/044304 A2	05-19-2005	Chiron Corporation		
	31	WO 2005/044306 A2	05-19-2005	Chiron Corporation		
	32	WO 2005/044307 A2	05-19-2005	Chiron Corporation		
	33	WO 2005/044854 A2	05-19-2005	Chiron Corporation		
	34	WO 2005/044855 A2	05-19-2005	Chiron Corporation		

- 1	Examiner	Date	
	Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 07/2007)				Complete if Known		
				Application Number	10/578,400	
INEOD	MATION	DISCLO	CLIDE	Filing Date	January 3, 2007	
INFORMATION DISCLOSURE				First Named Inventor	Long	
STATEMENT BY APPLICANT				Art Unit	1644	
(Use as many sheets as necessary)				Examiner Name	Gambel, Phillip	
Sheet	2	of	2	Attorney Docket Number	035784/311256	

		OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or exunty where published.			
	35	BALINT, R., et al., "Antibody Engineering by Parsimonious Mutagenesis," Gene, 1993, pp. 109-118, Vol. 137, No. 27.			
	36	ELLMARK, P., et al., "Modulation of the CD40-CD40 Ligand Interaction Using Human Anti-CD40 Single-Chain Antibody Fragments Obtained from the n-CoDeR Phage Display Library," Immunology, 2002, pp. 456-453, Vol. 106, No. 4.			
	37	HAGIER A-C MALMBORG, et al., "Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies," Scandinavian Journal of Immunology, 2003, pp. 517-524, Vol. 57, No. 6.			
	38	LITTLE, M., et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies," Review Immunology Today, 2000, pp. 364-370, Vol. 21.			

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.